Sunovion has announced that it will make its Zetonna ciclesonide nasal aerosol for the treatment of allergic rhinitis available in the US in time for the fall allergy season. The FDA approved Zetonna, an HFA formulation delivered by nasal pMDI, in January 2012.
Sunovion markets two other ciclesonide aerosols in the US: Omnaris nasal spray for the treatment of allergic rhinitis and Alvesco inhalation aerosol for the treatment of asthma.
Sunovion Vice Chair, Pharmaceuticals Hiroshi Nomura commented, “Sunovion is committed to providing treatments that help address the needs of the 60 million patients affected by allergic rhinitis in the US, and we are proud to be able to offer two options with different delivery systems to patients with this condition. These treatments, together with the existing asthma and chronic obstructive pulmonary disease therapies in Sunovion’s respiratory franchise, demonstrate our continued commitment to providing a full range of medications for patients with respiratory illnesses.”
Read the Sunovion press release.
